Cagrilintide dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 7 published studies are one click away.
Human trials Metabolic Also called NN9838, AM833, long-acting amylin analogue (in CagriSema)
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Trial reports agree on a 0.25 mg start, steps every 4 weeks, and 2.4 mg by week 16. The middle steps come from guides that cite the REDEFINE protocol. No approved label exists yet.
- Half-life
- Not on the site yet, being checked
- How it is taken
- subcutaneous injection
- How long people use it
- Step up every 4 weeks to 2.4 mg by week 16, then hold. REDEFINE 1 held the full dose for 52 weeks, 68 weeks in all.
- Mixing used for the units
- 10 mg vial + 2 mL water. 1 unit on a U-100 insulin syringe = 50 mcg.
Pick your vial size and how much water you add. The units below change to match.
10 mg vial + 2 mL water: 1 unit = 50 mcg
| Tier | Each dose | Syringe units10 mg vial + 2 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Step 1 [1] | 250 mcg | 5 units 0.05 mL | once a week | Weeks 1 to 4, once a week | 6+ weeks |
| Step 2 [2] | 500 mcg | 10 units 0.10 mL | once a week | Weeks 5 to 8, once a week | 6+ weeks |
| Step 3 [3] | 1 mg | 20 units 0.20 mL | once a week | Weeks 9 to 12, once a week | 6+ weeks |
| Step 4 [4] | 1.7 mg | 34 units 0.34 mL | once a week | Weeks 13 to 16, once a week | about 6 weeks |
| Maintenance [5] | 2.4 mg | 48 units 0.48 mL | once a week | Week 17 on, once a week. This was the target dose in REDEFINE 1, alone and with semaglutide. | about 4 weeks |
| Higher [6] | 4.5 mg | 90 units 0.90 mL | once a week | 4.5 mg once a week, the top arm of the phase 2 trial of cagrilintide alone | 15 days |
Good to know
- Given once a week.
- The CagriSema ladder uses the same steps for cagrilintide and semaglutide: 0.25, 0.5, 1.0, 1.7, then 2.4 mg.
- In REDEFINE 1, about 57% were still on the full dose at week 68. Others stayed lower because of nausea.
- Nausea peaks in the early steps. Slowing the climb is common.
- Not approved as a standalone drug anywhere.
Sources for these amounts
- Step 1: News-Medical, REDEFINE 1 results · Peptide Dosing Protocols, CagriSema
- Step 2: Peptide Dosing Protocols, CagriSema · Doctronic, cagrilintide dosage chart
- Step 3: Peptide Dosing Protocols, CagriSema · Doctronic, cagrilintide dosage chart
- Step 4: Peptide Dosing Protocols, CagriSema · Doctronic, cagrilintide dosage chart
- Maintenance: News-Medical, REDEFINE 1 results · Doctronic, cagrilintide with semaglutide
- Higher: Medical Dialogues, cagrilintide phase 2 (Lancet 2021)
How long people use it: News-Medical, REDEFINE 1 results · Applied Clinical Trials, REDEFINE 1
Take the Cagrilintide chart with you
Get a one-page printable chart for Cagrilintide, with the syringe units for each vial and water mix. We can also email you when a new Cagrilintide study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 7 published studies
Amounts given to people in studies
How it was given: Under the skin, once a week
Doses are stepped up over several weeks to the target dose. Most phase 3 trials pair 2.4 mg with semaglutide 2.4 mg.
Read this first. Most big trials tested it together with semaglutide (CagriSema). Alone, 4.5 mg weekly gave about 10.8% weight loss at 26 weeks. Nausea and other stomach side effects are common.
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 33894838Enebo et al, Lancet 2021 | Human, randomized phase 1b, 96 adults with overweight (with semaglutide 2.4 mg) | 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg | Under the skin | Once a week | 20 weeks (16 weeks step-up, 4 weeks at dose) | Half-life 159 to 195 h. Weight down 15.7% (1.2 mg) and 17.1% (2.4 mg) vs 9.8% semaglutide alone |
| PMID 34798060Lau et al, Lancet 2021 | Human, randomized phase 2, 706 adults on cagrilintide (100 to 102 per dose) | 0.3, 0.6, 1.2, 2.4 or 4.5 mg | Under the skin | Once a week | 26 weeks | Weight down 6.0% to 10.8% vs 3.0% placebo. 4.5 mg beat liraglutide 3.0 mg |
| PMID 37364590Frias et al, Lancet 2023 | Human, randomized phase 2, 92 adults with type 2 diabetes (30 on cagrilintide alone) | 2.4 mg (stepped up) | Under the skin | Once a week | 32 weeks | Cagrilintide alone: HbA1c down 0.9 points, weight down 8.1%. Combo did more |
| PMID 40544433Garvey et al, N Engl J Med 2025, REDEFINE 1 | Human, randomized phase 3a, 3417 adults with obesity (302 on cagrilintide alone) | 2.4 mg | Under the skin | Once a week | 68 weeks | Combo with semaglutide 2.4 mg: weight down 20.4% vs 3.0% placebo |
| PMID 40544432Davies et al, N Engl J Med 2025, REDEFINE 2 | Human, randomized phase 3a, 1206 adults with obesity and type 2 diabetes | 2.4 mg (with semaglutide 2.4 mg) | Under the skin | Once a week | 68 weeks | Weight down 13.7% vs 3.4% placebo. GI side effects in 72.5% |
| PMID 39279639Gabe et al, Diabetes Obes Metab 2024 | Human, randomized, 105 healthy adults (53 on cagrilintide) | Stepped up to 4.5 mg | Under the skin | Once a week | Until 4.5 mg reached | No meaningful QT (heart rhythm) change |
| PMID 42228334Nielsen et al, Clin Pharmacokinet 2026 | Human, 33 (kidney) and 32 (liver) adults | 0.6 mg (kidney study), 0.9 mg (liver study) | Under the skin | One time | Followed 36 to 39 days | Exposure about the same with kidney or liver impairment |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of Cagrilintide were used in human studies?
In the studies listed here, people were given from 0.16 mg under the skin once a week (with semaglutide 2.4 mg) up to 4.5 mg under the skin once a week. The amount used most often was 2.4 mg under the skin once a week. These are what study teams chose for their participants under supervision.
Where do these Cagrilintide numbers come from?
From 7 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
Is this a recommendation for how much Cagrilintide to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.